These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38244249)

  • 1. An investigation of 3M Cordova, IL production worker's per- and polyfluoroalkyl substances biomonitoring results and mortality experience.
    Andres KL; Olsen GW; Krisko RM; Nunnally MC; Boeding RR; Leniek KL; Taiwo OA
    Int J Hyg Environ Health; 2024 Mar; 256():114321. PubMed ID: 38244249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentrations of legacy and emerging per- and polyfluoroalkyl substances in the Anniston Community Health Surveys (ACHS I and ACHS II).
    Petriello MC; Mottaleb MA; Serio TC; Balyan B; Cave MC; Pavuk M; Birnbaum LS; Morris AJ
    Environ Int; 2022 Jan; 158():106907. PubMed ID: 34763231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Legacy and alternative per- and polyfluoroalkyl substances in the U.S. general population: Paired serum-urine data from the 2013-2014 National Health and Nutrition Examination Survey.
    Calafat AM; Kato K; Hubbard K; Jia T; Botelho JC; Wong LY
    Environ Int; 2019 Oct; 131():105048. PubMed ID: 31376596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PFAS (per- and polyfluoroalkyl substances) and asthma in young children: NHANES 2013-2014.
    Jackson-Browne MS; Eliot M; Patti M; Spanier AJ; Braun JM
    Int J Hyg Environ Health; 2020 Aug; 229():113565. PubMed ID: 32485600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum Half-Lives for Short- and Long-Chain Perfluoroalkyl Acids after Ceasing Exposure from Drinking Water Contaminated by Firefighting Foam.
    Xu Y; Fletcher T; Pineda D; Lindh CH; Nilsson C; Glynn A; Vogs C; Norström K; Lilja K; Jakobsson K; Li Y
    Environ Health Perspect; 2020 Jul; 128(7):77004. PubMed ID: 32648786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substances.
    Porter AK; Kleinschmidt SE; Andres KL; Reusch CN; Krisko RM; Taiwo OA; Olsen GW; Longnecker MP
    Environ Int; 2022 Nov; 169():107537. PubMed ID: 36183490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decline in perfluorooctanesulfonate and other polyfluoroalkyl chemicals in American Red Cross adult blood donors, 2000-2006.
    Olsen GW; Mair DC; Church TR; Ellefson ME; Reagen WK; Boyd TM; Herron RM; Medhdizadehkashi Z; Nobiletti JB; Rios JA; Butenhoff JL; Zobel LR
    Environ Sci Technol; 2008 Jul; 42(13):4989-95. PubMed ID: 18678038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occupational exposure to perfluoroalkyl substances and serum levels of perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) in an aging population from upstate New York: a retrospective cohort study.
    Tanner EM; Bloom MS; Wu Q; Kannan K; Yucel RM; Shrestha S; Fitzgerald EF
    Int Arch Occup Environ Health; 2018 Feb; 91(2):145-154. PubMed ID: 29027000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000.
    Calafat AM; Wong LY; Kuklenyik Z; Reidy JA; Needham LL
    Environ Health Perspect; 2007 Nov; 115(11):1596-602. PubMed ID: 18007991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Per- and polyfluoroalkyl substances in blood plasma - Results of the German Environmental Survey for children and adolescents 2014-2017 (GerES V).
    Duffek A; Conrad A; Kolossa-Gehring M; Lange R; Rucic E; Schulte C; Wellmitz J
    Int J Hyg Environ Health; 2020 Jul; 228():113549. PubMed ID: 32502942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated measurements of per- and polyfluoroalkyl substances (PFASs) from 1979 to 2007 in males from Northern Norway: assessing time trends, compound correlations and relations to age/birth cohort.
    Nøst TH; Vestergren R; Berg V; Nieboer E; Odland JØ; Sandanger TM
    Environ Int; 2014 Jun; 67():43-53. PubMed ID: 24657493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human biomonitoring of per- and polyfluoroalkyl substances in German blood plasma samples from 1982 to 2019.
    Göckener B; Weber T; Rüdel H; Bücking M; Kolossa-Gehring M
    Environ Int; 2020 Dec; 145():106123. PubMed ID: 32949877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure to Per- and Polyfluoroalkyl Substances and Mortality in U.S. Adults: A Population-Based Cohort Study.
    Wen X; Wang M; Xu X; Li T
    Environ Health Perspect; 2022 Jun; 130(6):67007. PubMed ID: 35731224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentrations of legacy, alternative, and precursor per- and polyfluoroalkyl substances: a descriptive analysis of adult female participants in the MIREC-ENDO study.
    Borghese MM; Ward A; MacPherson S; Manz KE; Atlas E; Fisher M; Arbuckle TE; Braun JM; Bouchard MF; Ashley-Martin J
    Environ Health; 2024 Jun; 23(1):55. PubMed ID: 38858670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Per- and polyfluoroalkyl substances (PFAS) in Australia: Current levels and estimated population reference values for selected compounds.
    Toms LML; Bräunig J; Vijayasarathy S; Phillips S; Hobson P; Aylward LL; Kirk MD; Mueller JF
    Int J Hyg Environ Health; 2019 Apr; 222(3):387-394. PubMed ID: 30898527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Legacy and alternative per- and polyfluoroalkyl substances (PFAS) alter the lipid profile of HepaRG cells.
    Kashobwe L; Sadrabadi F; Brunken L; Coelho ACMF; Sandanger TM; Braeuning A; Buhrke T; Öberg M; Hamers T; Leonards PEG
    Toxicology; 2024 Aug; 506():153862. PubMed ID: 38866127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlates of plasma concentrations of per- and poly-fluoroalkyl substances among reproductive-aged Black women.
    Wise LA; Wesselink AK; Schildroth S; Calafat AM; Bethea TN; Geller RJ; Coleman CM; Fruh V; Claus Henn B; Botelho JC; Harmon QE; Thirkill M; Wegienka GR; Baird DD
    Environ Res; 2022 Jan; 203():111860. PubMed ID: 34403666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Internal Relative Potency Factors for the Risk Assessment of Mixtures of Per- and Polyfluoroalkyl Substances (PFAS) in Human Biomonitoring.
    Bil W; Zeilmaker MJ; Bokkers BGH
    Environ Health Perspect; 2022 Jul; 130(7):77005. PubMed ID: 35881550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomonitoring of perfluoroalkyl and polyfluoroalkyl substances (PFAS) from the Survey of the Health of Wisconsin (SHOW) 2014-2016 and comparison with the National Health and Nutrition Examination Survey (NHANES).
    Schultz AA; Stanton N; Shelton B; Pomazal R; Lange MA; Irving R; Meiman J; Malecki KC
    J Expo Sci Environ Epidemiol; 2023 Sep; 33(5):766-777. PubMed ID: 37580384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Internal relative potency factors based on immunotoxicity for the risk assessment of mixtures of per- and polyfluoroalkyl substances (PFAS) in human biomonitoring.
    Bil W; Ehrlich V; Chen G; Vandebriel R; Zeilmaker M; Luijten M; Uhl M; Marx-Stoelting P; Halldorsson TI; Bokkers B
    Environ Int; 2023 Jan; 171():107727. PubMed ID: 36628859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.